|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gemcitabine had distinct toxicogenomic effects in the bladder transitional carcinoma cell lines with two different TP53 mutations.
|
23053941 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The presence and distribution of high-risk human papillomavirus (HPV) DNA type-16 and -18 or overexpression of the p53 protein were determined in 31 patients with renal pelvic and ureteral carcinoma in Saga prefecture of Japan, consisting of 28 transitional cell carcinomas (TCCs) and 3 squamous cell carcinomas (SCCs).
|
9852285 |
1998 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study evaluated the relationship between p53 Ser392 phosphorylation and various types of p53 missense mutation detected in urothelial transitional cell carcinomas (TCCs), with stratification of the mutations according to the functional domains elucidated by the crystal structure of the p53 protein.
|
12081208 |
2002 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transitional cell carcinoma (TCC) of the bladder in younger patients has historically a favourable prognosis. bcl-2 and p53 genes are implicated in cell cycle regulation with roles on programmed cell death.
|
11464113 |
2001 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the frequency of p53 nuclear overexpression in BBC is lower than that reported for conventional transitional cell carcinoma.
|
9815716 |
1997 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to determine whether ploidy, MIB-1 proliferative activity, or p53 protein staining in inverted papilloma were predictive of urothelial carcinoma.
|
10649258 |
2000 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, there was no association of p53 or CCND1 polymorphisms with UC risk.
|
18640142 |
2008 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
This prompted our investigation to explore the global Alu methylation and the promoter methylation of the novel putative tumor suppressor genes caveolin-1 and hDAB2IP, and of p53 in transitional cell carcinomas (TCC), squamous cell carcinomas and undifferentiated small cell carcinomas of the urinary bladder.
|
16328005 |
2006 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ninety-four patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter, including dysplastic lesions, were studied for p53 and bcl-2 protein expression by immunohistochemistry.
|
8683378 |
1996 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Between January 1999 and December 2008, 275 patients who received six BCG intravesical instillations for NMIBC (transitional cell carcinoma) after transurethral resection were assessed for differences in outcomes according to the level of p53 overexpression.
|
21487231 |
2010 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
|
23357513 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this article, we review the roles of p53 pathways in bladder carcinogenesis and findings from recent studies of ours and other groups, and we discuss the clinical significance of the abrogation of p53 pathways in the treatment of urothelial carcinoma.
|
18704627 |
2008 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
|
9649138 |
1998 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with transitional-cell carcinoma confirmed to the bladder that demonstrates nuclear p53 reactivity should be considered for protocols of adjuvant treatment.
|
7935683 |
1994 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma.
|
10675480 |
2000 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic losses in chromosome arm 17p, where the p53 gene resides, were found to be less frequent in squamous cell carcinomas (38%) than in invasive transitional cell carcinomas (60%).
|
7658499 |
1995 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis.
|
10830781 |
2000 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We studied to determine whether Arg72 could be a risk factor for p53 mutations in human transitional cell carcinomas (TCCs).
|
12006537 |
2002 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess the value of p53 mutations in predicting the progression of superficial bladder cancer [transitional cell carcinoma (TCC)] and to define exactly when p53 mutations occur in the process of tumor progression, 80 consecutive bladder washings from 26 high-risk (indicated by quantitative karyometric analysis) superficial TCC patients were examined by single-strand conformation polymorphism.
|
9816267 |
1996 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
A simple analysis of the p53 gene using PCR/SSCP is suitable for screening for p53 abnormalities in transitional cell carcinoma.
|
15825690 |
2005 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequent presence of UroVysion FISH abnormalities, urothelial carcinoma in situ, and p53 positivity by immunohistochemistry in cases of urinary tract LELC suggests a similar pathogenesis to high-grade invasive urothelial carcinoma.
|
21383609 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in p53 represent a highly promising marker of disease recurrence and cancer specific mortality after radical cystectomy for urothelial carcinoma of the bladder.
|
19616250 |
2009 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the p53 gene related to neoplastic progression were studied in tumor tissue samples from patients with transitional cell carcinoma and correlated with classic staging parameters.
|
12544295 |
2003 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of p53, normally secondary to gene mutation, in invasive uroepithelial neoplasms (transitional cell carcinoma) and a high percentage of transitional cell carcinoma in situ (CIS) has been described; however, the role of p53 before and after bacillus Calmette-Guérin (BCG) treatment of CIS needs to be defined.
|
9111623 |
1997 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results were compared to the mutation frequency of TP53 in urine sediments from patients diagnosed with transitional cell carcinoma (TCC) of the bladder and healthy controls.
|
16903935 |
2006 |